Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.63 |
| ▸ | CNR1 | P21554 | 3/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | GPR6 | P46095 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937097 | 0.85 | SLC6A9 (0.61) | SLC6A9CNR1GPR55ALDH1A1MEN1 | |
| SCHEMBL1381763 | 0.81 | SLC6A9 (0.61) | SLC6A9 | |
| SCHEMBL4058122 | 0.81 | SLC6A9 (0.56) | SLC6A9GPR6 | |
| SCHEMBL4930192 | 0.81 | SLC6A9 (0.65) | SLC6A9CNR1GPR55ALDH1A1MEN1 | |
| SCHEMBL1377168 | 0.80 | SLC6A9 (0.57) | SLC6A9 | |
| SCHEMBL4933947 | 0.79 | SLC6A9 (0.62) | SLC6A9CNR1GPR55ALDH1A1MEN1 | |
| SCHEMBL4938899 | 0.79 | SLC6A9 (0.72) | SLC6A9 | |
| SCHEMBL4939156 | 0.78 | SLC6A9 (0.61) | SLC6A9CNR1GPR55ALDH1A1MEN1 | |
| SCHEMBL3920651 | 0.78 | SLC6A9 (1.00) | SLC6A9GPR55 | |
| SCHEMBL3923127 | 0.76 | SLC6A9 (0.98) | SLC6A9GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| WO-2006094843-A1 | PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | SLC6A7, SLC6A5, SLC1A2 | SLC6A9 22/4885CNR1 351/4885GPR55 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.